Bayer's Legal and Operational Crossroads Converge in Late April
21.04.2026 - 13:12:07 | boerse-global.de
Bayer shares, trading at €41.37, find themselves in a technically oversold position as the company enters a decisive phase. The Relative Strength Index (RSI) reading of 23.3 underscores the market's tension ahead of two pivotal late-April events that will shape the German conglomerate's immediate future.
The primary focus is a landmark hearing at the US Supreme Court scheduled for April 27. The justices will consider Bayer's argument that the federal FIFRA law preempts state-level failure-to-warn claims regarding its glyphosate-based herbicide, Roundup. A ruling in Bayer's favor could invalidate tens of thousands of lawsuits alleging the product causes cancer. The Trump administration has notably backed Bayer's legal stance, reversing the position of the previous government. A final decision from the high court is expected by this summer.
The financial stakes are colossal. Analysts estimate the total monetary risk from the Monsanto litigation complex remains as high as €24 billion. To date, the acquisition has already cost Bayer over $11 billion in settlements and penalties. The company has provisioned an additional €11.8 billion for ongoing cases. Market speculation suggests a comprehensive settlement could be reached for around $7.5 billion. Management itself anticipates cash outflows of approximately €5 billion this year for glyphosate-related settlements, which will significantly pressure free cash flow.
Should investors sell immediately? Or is it worth buying Bayer?
Preceding the court date, Bayer will hold its virtual Annual General Meeting on April 24. The company is now in a quiet period ahead of the event. Shareholders are set to approve a nominal dividend of €0.11 per share, with the ex-dividend date falling on the following Monday. The meeting will also see a reshuffle of the supervisory board, with Marcel Smits and Alfred Stern nominated to replace Paul Achleitner and Colleen Goggins, aiming to strengthen the panel during the ongoing corporate transformation.
Amid the legal turmoil, Bayer's operational business shows robust signs of life. The pharmaceutical division is delivering strong growth, particularly for the kidney and heart drug Kerendia, which posted currency-adjusted growth of 88% recently. Bayer sees peak sales potential for this product exceeding €3 billion. Another key pipeline asset, the anticoagulant asundexian, demonstrated promising results in a pivotal study with over 12,000 participants, reducing stroke risk by 26%. The US FDA has already granted the drug Fast-Track status.
Despite the year's challenges, the management team reaffirms its annual guidance. This outlook is partly supported by trade agreements that cap potential US tariffs on pharmaceuticals at 15%. The company has also made progress on its balance sheet, reducing its net financial debt to just under €30 billion by the end of last year, though financial flexibility remains constrained.
Looking ahead, Bayer's calendar remains packed. The company will report first-quarter figures on May 12. June 4 marks the deadline for claimants to opt out of a nationwide settlement program. The convergence of these legal, financial, and operational milestones in the coming weeks will determine whether Bayer can finally begin to move beyond its most burdensome legacy issue.
Ad
Bayer Stock: New Analysis - 21 April
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
So schätzen die Börsenprofis Bayers Aktien ein!
Für. Immer. Kostenlos.
